Tag Archives: Johnson & Johnson

Patents Not an Issue in the Fight Against Ebola

shutterstock_26191726

As of October 23,2014 more than 4,900 people have died from the current Ebola outbreak, concentrated in the three West African countries of Sierra Leone, Guinea, and Liberia. Frustrated that the process of getting experimental vaccines to West Africa was not moving fast enough, some were quick to blame intellectual property rights. But in reality, as government officials were quick to point out, the WHO first needed to resolve important ethical and safety considerations before a vaccine that Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , , , , , , , , ,

Fireside Chat with Ken Drazan, MD, Head of Johnson & Johnson Innovation

Ken Drazan, MD

Day one of the BIO Investor Forum featured a Fireside Chat with Ken Drazan, MD, who serves as the head of Johnson & Johnson Innovation in California. The conversation was moderated by Deepa R. Pakianathan, PhD, a general partner for Delphi Ventures who leads the firm’s biotechnology investment activities. Ken Drazan has a unique viewpoint which results from having experience with both the biopharma start-up world as well as in the investment community. This background Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

My Regeneration

brain-scan

What can today’s generation hope for from regenerative medicine? It’s a frontier for business, the medical profession and society. Regenerative medicine aims to shift the focus from palliative care to the development of treatments that address diabetes, Parkinson’s disease, stroke and heart disease. The hope is that we’ll live longer, healthier lives and have greater independence in old age, thereby reducing the burden on healthcare systems. Given global population demographics, this is essential: according to the World Health Organisation by Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , ,